The effect of sildenafil on pulmonary haemodynamics in a canine model of chronic embolic pulmonary hypertension

被引:8
作者
Akabane, Ryota [1 ]
Sakatani, Atsushi [1 ]
Ogawa, Mizuki [1 ]
Nagakawa, Masayoshi [1 ]
Miyakawa, Hirosumi [1 ]
Miyagawa, Yuichi [1 ]
Takemura, Naoyuki [1 ]
机构
[1] Vet & Life Sci Univ, Sch Vet Med, Lab Vet Internal Med 2, 1-7-1 Kyonan Cho, Musashino, Tokyo 1808602, Japan
关键词
Dog; Microspheres; Pulmonary hypertension; Right heart catheterisation; Sildenafil; ARTERIAL-HYPERTENSION; CITRATE THERAPY; DOGS; DOPPLER;
D O I
10.1016/j.rvsc.2020.08.019
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
The effects of different doses of orally administered sildenafil on pulmonary haemodynamics in dogs with pulmonary hypertension (PH) have not been documented in an invasive and quantitative manner. In this study, we examined the effects of oral sildenafil using a canine model of chronic embolic PH (CEPH). This CEPH model was created by repeatedly injecting microspheres through a catheter into the pulmonary artery under general anaesthesia at regular weekly intervals over several months. The CEPH dogs received 1, 2 or 4 mg/kg of sildenafil orally twice a day for seven days. Then, haemodynamic measurements including pulmonary artery pressure (PAP), systemic artery pressure (SAP), pulmonary artery wedge pressure (PAWP), right atrial pressure (RAP) and cardiac output (CO) were obtained after seven days of sildenafil administration via right heart catheterisation and oscillometric blood pressure measurements. Sildenafil was well tolerated in this study. Sildenafil administered at doses of 2 and 4 mg/kg significantly decreased systolic PAP compared with before administration. In addition, all doses of sildenafil significantly decreased the mean and diastolic PAP. Furthermore, 4 mg/kg of sildenafil significantly decreased PAP compared with 1 mg/kg. Sildenafil also significantly decreased pulmonary vascular resistance without notable changes in SAP or systemic vascular resistance. The PAWP, RAP and CO did not increase significantly at any doses. In conclusion, the oral administration of sildenafil to CEPH models decreased PAP in a dose-dependent manner.
引用
收藏
页码:106 / 110
页数:5
相关论文
共 30 条
[1]   Pharmacokinetics of single dose sildenafil orally administered in canine models of chronic embolic pulmonary hypertension [J].
Akabane, Ryota ;
Sato, Touko ;
Sakatani, Atsushi ;
Ogawa, Mizuki ;
Nagakawa, Masayoshi ;
Miyakawa, Hirosumi ;
Miyagawa, Yuichi ;
Tazaki, Hiroyuki ;
Takemura, Naoyuki .
JOURNAL OF VETERINARY MEDICAL SCIENCE, 2020, 82 (04) :446-451
[2]  
Bach JF, 2006, J VET INTERN MED, V20, P1132, DOI 10.1892/0891-6640(2006)20[1132:REOSCA]2.0.CO
[3]  
2
[4]   Prevalence and Prognostic Importance of Pulmonary Hypertension in Dogs with Myxomatous Mitral Valve Disease [J].
Borgarelli, M. ;
Abbott, J. ;
Braz-Ruivo, L. ;
Chiavegato, D. ;
Crosara, S. ;
Lamb, K. ;
Ljungvall, I. ;
Poggi, M. ;
Santilli, R. A. ;
Haggstrom, J. .
JOURNAL OF VETERINARY INTERNAL MEDICINE, 2015, 29 (02) :569-574
[5]   Clinical Efficacy of Sildenafil in Treatment of Pulmonary Arterial Hypertension in Dogs [J].
Brown, A. J. ;
Davison, E. ;
Sleeper, M. M. .
JOURNAL OF VETERINARY INTERNAL MEDICINE, 2010, 24 (04) :850-854
[6]   Pharmacokinetic evaluation of sildenafil as a pulmonary hypertension treatment [J].
Chaumais, Marie-Camille ;
Perrin, Swanny ;
Sitbon, Olivier ;
Simonneau, Gerald ;
Humbert, Marc ;
Montani, David .
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2013, 9 (09) :1193-1205
[7]   Sildenafil selectively inhibits acute pulmonary embolism-induced pulmonary hypertension [J].
Dias-Junior, CA ;
Vieira, TF ;
Moreno, H ;
Evora, PR ;
Tanus-Santos, JE .
PULMONARY PHARMACOLOGY & THERAPEUTICS, 2005, 18 (03) :181-186
[8]   Comparison between two methods for cardiac output measurement in propofol-anesthetized dogs: thermodilution and Doppler [J].
Ferro Lopes, Patricia Cristina ;
Sousa, Marlos Goncalves ;
Camacho, Aparecido Antonio ;
Carareto, Roberta ;
Nishimori, Celina T. D. ;
Santos, Paulo S. P. ;
Nunes, Newton .
VETERINARY ANAESTHESIA AND ANALGESIA, 2010, 37 (05) :401-408
[9]   Sildenafil citrate therapy for pulmonary arterial hypertension [J].
Galiè, N ;
Ghofrani, HA ;
Torbicki, A ;
Barst, RJ ;
Rubin, LJ ;
Badesch, D ;
Fleming, T ;
Parpia, T ;
Burgess, G ;
Branzi, A ;
Grimminger, F ;
Kurzyna, M ;
Simonneau, G .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (20) :2148-2157
[10]   2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT) [J].
Galie, Nazzareno ;
Humbert, Marc ;
Vachiery, Jean-Luc ;
Gibbs, Simon ;
Lang, Irene ;
Torbicki, Adam ;
Simonneau, Gerald ;
Peacock, Andrew ;
Noordegraaf, Anton Vonk ;
Beghetti, Maurice ;
Ghofrani, Ardeschir ;
Gomez Sanchez, Miguel Angel ;
Hansmann, Georg ;
Klepetko, Walter ;
Lancellotti, Patrizio ;
Matucci, Marco ;
McDonagh, Theresa ;
Pierard, Luc A. ;
Trindade, Pedro T. ;
Zompatori, Maurizio ;
Hoeper, Marius .
EUROPEAN HEART JOURNAL, 2016, 37 (01) :67-+